Market rumors have been confirmed. On March 9, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) announced that it signed a supply agreement with Pfizer on March 9.
The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022). Paxlovid, taken within three days after the onset of symptoms, can reduce the probability of hospitalization or death of mild and moderate adult patients by 89%.
China Meheco Group Co.Ltd(600056) will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market during the term of the agreement (2022). China Meheco Group Co.Ltd(600056) said that the final use and sales of products are affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the scale of relevant business accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance, and the company’s main business will not rely on the counterparty due to such transactions
The subject of this agreement is covid-19 virus treatment drug paxlovid On February 11, 2022, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and approved the import registration of Pfizer’s product conditionally.
The market has been hyping China Meheco Group Co.Ltd(600056) . Under the condition of poor market performance, the stock price rose for four consecutive days. On the 8th and 9th, the stock price still rose. On the 9th, it closed at 17.3 yuan, up 2.55%.
Paxlovid is a compound preparation of 3CL protease inhibitor nirmatrelvir and low-dose ritonavir. It is administered in combination with 300mg (two 150mg tablets) nirmatrelvir and one 100mg ritonavir tablet for covid-19 patients. It is administered twice a day for 5 days. Ritonavir helps to slow down the metabolism or decomposition of nirmatrelvir, Maintain its effective concentration in the body for a long time to fight the virus for a long time. On December 22, 2021 local time, the US FDA announced that it had approved Pfizer’s emergency authorization application (EUA) for a new oral antiviral candidate of covid-19, paxlovid, for the treatment of covid-19 infection in non hospitalized adults at high risk of developing into severe diseases. This is also the first covid-19 oral antiviral drug approved by FDA. According to the data released by Pfizer at the end of 2021, paxlovid taken within three days after the onset of symptoms can reduce the probability of hospitalization or death of mild and moderate adult patients by 89% compared with placebo.
announcement shows that on February 11, 2022, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and approved the import registration of Pfizer’s products with conditions
According to the State Food and drug administration, it is an oral small molecule COVID-19 virus treatment for adults with mild to moderate New Coronavirus pneumonia with severe risk factors, such as elderly, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease.
AVIC Securities said that according to the announcement and annual report previously released by Pfizer, the price of a single course of paxlovid is $529. It is expected that the revenue of covid-19 oral medicine will reach $22 billion in covid-19 treatment products in 2022. Covid-19 oral medicine, as the last puzzle in the current covid-19 treatment industry chain, has broad market prospects.
China Meheco Group Co.Ltd(600056) today, it was also announced that Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a notice of approval for supplementary application for sodium risedronate tablets approved and issued by the State Drug Administration, which passed the evaluation of the consistency of quality and efficacy of generic drugs.
on January 29, China Meheco Group Co.Ltd(600056) released the announcement of performance reduction in 2021. The company expects the net profit in 2021 to be 300 million yuan to 700 million yuan, a year-on-year decrease of 77% to 47%
\u3000\u3000
